Goel, S., Testa, L., Damian, F., Voon, P. J., Suzuki, D. A., Hegg, R., Ribeiro, D., Rodrigues, H., Bines, J., Bulat, I. V., Gao, H., Chaudhary, S., Schnell, P., Deng, T., Zheng, H., Yap, T. A. (2026). First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2− breast cancer (BC): A phase 1 safety expansion.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1066